Sarda Proteins Limited reported a standalone net profit of ₹68.60 lakh for the quarter ended March 31, 2026 (Q4FY26), marking a significant turnaround from a net loss of ₹11.23 lakh in the corresponding quarter of FY25. The Alwar-based renewable energy player also posted a full-year net profit of ₹45.44 lakh for FY26, up from ₹0.50 lakh in FY25. The improved profitability was supported by higher interest income and operational efficiencies, while the company executed a major equity raise that substantially strengthened its balance sheet.

The Board of Directors approved the audited financial results in a meeting held on April 30, 2026. Sarda Proteins subsequently submitted revised results to the BSE on August 05, 2026, citing clerical corrections related to the booking of interest income and the reclassification of share warrants as equity. The company stated that these revisions do not have a material impact on its overall financial position.

Financial Performance

Revenue from operations for Q4FY26 stood at ₹65.00 lakh, compared to nil in Q4FY25. For the full year FY26, revenue from operations was ₹1,615.84 lakh, down from ₹2,419.10 lakh in FY25. However, other income surged to ₹34.90 lakh for the year, up from ₹0.06 lakh in the previous year, primarily due to interest income. Total expenses for Q4FY26 were ₹5.26 lakh, resulting in a profit before tax of ₹84.10 lakh. After providing for current tax expenses of ₹15.50 lakh, the net profit for the quarter came in at ₹68.60 lakh.

Balance Sheet and Cash Flow

The company’s balance sheet underwent a significant transformation during FY26. Total assets rose to ₹8,665.52 lakh as of March 31, 2026, from ₹264.81 lakh at the end of FY25. This increase was largely driven by cash and cash equivalents, which jumped to ₹751.92 lakh from ₹3.38 lakh, and other current assets (advances), which stood at ₹7,474.59 lakh compared to ₹249.39 lakh in the prior year. Trade receivables were recorded at ₹414.16 lakh.

Equity capital increased to ₹975.45 lakh from ₹250.45 lakh, following proceeds from the issue of share capital including securities premium amounting to ₹8,315.45 lakh during the year. Reserves and surplus turned positive at ₹7,645.29 lakh, recovering from a deficit of ₹12.65 lakh in FY25. Total liabilities remained low at ₹44.78 lakh, with borrowings at ₹15.50 lakh.

What the Numbers Show

The financial data reveals a strategic shift from operations-led growth to capital-raising activities. While revenue from operations declined by approximately 33% year-on-year, the company generated substantial cash inflows through equity issuance. The surge in other income, specifically interest income, contributed significantly to the bottom line, indicating that the newly raised capital is beginning to yield returns. The reclassification of share warrants as equity, noted in the revised filing, further underscores the structural changes in the company’s capital base during this period.

Sarda Proteins Ltd will consider raising its authorised equity share capital to ₹100 crore in a board meeting scheduled for July 4, 2026. The proposal seeks to increase the capital from the existing ₹13 crore, a move aimed at expanding the company's financial base for future requirements. The board will also deliberate on altering the object clause of the Memorandum of Association to align with potential business expansion strategies.

The meeting, convened pursuant to Regulation 29 of the SEBI (LODR) Regulations, 2015, will see the board approve the draft notice for an Extraordinary General Meeting (EGM). Shareholders will be voting on the proposed capital increase and alterations to the Memorandum of Association. The board is also scheduled to appoint a scrutinizer to oversee the voting process during the EGM.

Key Agenda Items

The board meeting will focus on four primary resolutions:

• Increase in Authorised Capital: Raising the limit from ₹13,00,00,000 to ₹1,00,00,00,000.
• Alteration of MOA: Modifying the object clause to reflect new business objectives.
• EGM Notice: Approval of the draft notice to convene the Extraordinary General Meeting.
• Scrutinizer Appointment: Selecting an official to conduct the postal ballot or e-voting process.

Financial Implications

The decision to enhance the authorised capital indicates the management's intent to raise equity funds in the near future. While the current authorised capital stands at ₹13 crore, the proposed increase to ₹100 crore provides the necessary headroom for issuing new shares. This strategic step is often taken to facilitate funding for acquisitions, debt reduction, or capital expenditure.

The intimation was submitted to BSE Limited by Chirag Thummar, Managing Director of Sarda Proteins Ltd. The filing confirms that the meeting will be held to finalize the procedural requirements for the EGM, ensuring compliance with regulatory standards.